Tenax Therapeutics Conference Call Summary Company Overview - **Company**: Tenax Therapeutics (NasdaqCM:TENX) - **Event**: 2026 Conference on March 10, 2026 - **Speakers**: Christopher Giordano (CEO), Stuart Rich (Chief Medical Officer) Key Points Industry and Product Focus - **Industry**: Pharmaceutical, specifically focusing on treatments for pulmonary hypertension and heart failure - **Product**: Oral levosimendan, aimed at treating patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) [1][2] Enrollment and Study Updates - **LEVEL Study Enrollment**: Achieved target of 230 PH-HFpEF patients randomized, completed ahead of schedule in approximately 2 years [2] - **Study Timeline**: Randomization expected to conclude in March, with results anticipated in the third quarter of 2026 [2] - **Patient Retention**: High retention rate in the trial, with over 90% of patients entering the open-label extension (OLE) phase [16][17] Financial Health - **Liquidity**: Improved liquidity since PIPE financing, with sufficient cash to fund operations for approximately 18 months beyond data readout [3] Mechanism of Action - **Mechanism**: Oral levosimendan works by redistributing blood volume from splanchnic circulation to the lungs, addressing the issue of pulmonary hypertension in PH-HFpEF patients [11][12] - **Clinical Evidence**: Previous trials (HELP) demonstrated that levosimendan effectively reduces right atrial pressure and pulmonary artery pressure while maintaining cardiac output [13][14] Patient Experience and Anecdotal Evidence - **Patient Feedback**: Patients report significant improvements in quality of life, with anecdotes of increased activity levels and ability to perform daily tasks [53] - **Placebo Effect Considerations**: Patient responses can vary based on their initial health status; sicker patients are less likely to improve on placebo [19] Statistical Analysis and Trial Design - **Sample Size Reassessment**: Adjusted sample size based on interim analysis, increasing the power of the study to over 90% [30][35] - **Expected Outcomes**: Targeting a 25-meter improvement in the six-minute walk test, which is considered clinically meaningful for this patient population [37] Global Expansion Plans - **Future Trials**: Plans for LEVEL Two trial with a larger footprint, aiming to recruit in multiple countries including the U.S., Europe, Korea, and Taiwan [57][58] - **Recruitment Strategy**: Leveraging existing relationships with pulmonary hypertension experts to enhance recruitment efforts [59] Regulatory Considerations - **FDA Interactions**: Ongoing discussions with regulatory experts regarding potential pathways for drug approval, including the possibility of rolling submissions based on safety data [69][70] Company Growth and Structure - **Workforce Expansion**: Tripled employee count since raising funds, focusing on building relationships with investigators and opinion leaders globally [73][75] - **Commercialization Strategy**: Preparing for global commercialization with a focus on pre-commercial relationship management and medical teams [75] Additional Insights - **Market Potential**: Approximately 80% of HFpEF patients may have pulmonary hypertension, indicating a significant market opportunity for oral levosimendan if approved [23][24] - **Patient Demographics**: LEVEL trial participants are less symptomatic compared to those in the HELP trial, which may influence treatment outcomes [22] This summary encapsulates the critical insights from the Tenax Therapeutics conference call, highlighting the company's advancements, study progress, and strategic plans within the pharmaceutical industry.